I'm Still on a GLP-1 Medication — What Does That Mean for a Claim?

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

Your Stomach Symptoms Were Real

If you took brand-name Ozempic, Wegovy, or Rybelsus and were diagnosed with a tested, documented stomach injury with an ER or hospital visit, you may qualify.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

Active use is not a disqualifier in either track. For NAION vision-loss claims, a diagnosis made while taking the medication qualifies under current criteria. For stomach-injury claims, a diagnosis made while taking the medication satisfies the timing requirement by definition. Whether to stay on the medication, change it, or stop it is a medical decision between you and your prescriber — we do not advise on it, and nothing about a claim requires you to make that decision one way or the other.

The one thing we will not do

We will not tell you to stop taking your medication, and we will not tell you to keep taking it. That is a medical decision to be made with your prescriber, and it belongs to the two of you.

We say that plainly because it is what people expect to be asked the moment they mention they are still on it, and because a law firm is not the right source for that answer. A GLP-1 is managed for blood sugar, weight, and sometimes cardiovascular risk; changing it has real clinical consequences. Your physician knows your history and we do not. What we can do is tell you accurately how active use interacts with the screening criteria, so you are not deciding anything based on a guess.

How active use reads under each track’s criteria

Stomach injuries (gastroparesis or gastric obstruction)

The criteria require the diagnosis to have been made while taking the medication or within about 30 days of stopping. If you are currently taking the medication and were diagnosed at any point during that period of use, that element is met — continuing use makes the timing question simpler, not harder.

The other requirements still apply independently: brand-name Ozempic, Wegovy, or Rybelsus rather than compounded or generic semaglutide; gastroparesis confirmed by a gastric emptying study, or gastric obstruction confirmed by objective testing; a related emergency-room visit or hospital admission; a diagnosis made before December 31, 2024; and an age of 75 or under at intake.

NAION (sudden optic-nerve vision loss)

The criteria accept a diagnosis made while taking the medication or after stopping it, with no stated cutoff date. They require an actual NAION diagnosis, some degree of permanent vision impairment, and brand-name use of Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound.

Being on it now is an advantage for the record

People still on a prescription usually have what claimants who stopped years ago must reconstruct: a live, accessible paper trail.

• Your pharmacy fill history is current and can be printed on request — the cleanest proof of brand and dates that exists.
• Your prescriber’s chart is active, with recent visit notes, dose changes, and any symptom complaints already documented in real time.
• The physical packaging is likely still in your home. Keep pens, boxes, cartons, labels and receipts rather than discarding them.
• Any ongoing testing or specialist follow-up is being generated now, contemporaneously, which is the most durable kind of documentation.

None of that requires changing anything about your treatment. It means the evidence is close at hand rather than buried.

Privacy, and the question of who has to know

A case review is confidential. Speaking with us does not notify your prescriber, your pharmacy, your employer, or your insurer, and it does not create an attorney-client relationship by itself. If a claim moves forward, medical records are requested through the ordinary release process — the same routine request anyone makes when changing practices — and you would know about it in advance.

Many people have not told anyone in their life that they take a GLP-1. That is common enough to be unremarkable, and it does not complicate anything on our end.

Where the litigation actually stands

No GLP-1 case has settled and none has been tried. In August 2025 the court overseeing the stomach-injury cases ruled that a gastroparesis claim must be based on a properly performed gastric emptying study rather than symptoms alone — a documentation requirement imposed on claims, not a judgment about anyone’s illness. A Rule 702 hearing on expert evidence in that proceeding is underway September 14 through 18, 2026.

The NAION proceeding, created in December 2025, has issued no merits rulings. European regulators concluded in June 2025 that NAION is a very rare side effect of semaglutide medicines. The manufacturers dispute causation in both tracks.

Common questions

Common questions: can you sue?, it’s not about your doctor, still taking Ozempic?, is it too late to file?, stopped taking it, switched drugs, calling for a parent, and how compensation works.